Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MoonLake Immunotherapeutics - Class A Ordinary Shares (NQ:MLTX)

13.08 +0.31 (+2.43%)
Streaming Delayed Price Updated: 11:10 AM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MoonLake Immunotherapeutics - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Unusual volume stocks are being observed in Thursday's session. ↗
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
News headline image
MOONLAKE ALERT: Bragar Eagel & Squire, P.C. Announces Investigation into MoonLake Immunotherapeutics on Behalf of MoonLake Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
MoonLake Immunotherapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX
From DJS Law Group
Via Business Wire
MoonLake Stock Climbs After-Hours: Retail Traders Shrug Off Record Plunge, More Wall Street Downgrades ↗
Via Stocktwits
MoonLake Immunotherapeutics Stock Draws Buzz After Skin Drug’s Phase 3 Trial Data — Retail Speculates Buyout, Bigger Gains ↗
Via Stocktwits
News headline image
MoonLake Investor News: Rosen Law Firm Encourages MoonLake Immunotherapeutics Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – MLTX
From Rosen Law Firm
Via Business Wire
News headline image
MLTX Investors Have Opportunity to Join MoonLake Immunotherapeutics Fraud Investigation with the Schall Law Firm
From Schall Law Firm
Via Business Wire
News headline image
Unusual volume stocks are being observed in Wednesday's session. ↗
Discover the stocks with unexpected trading volume in today's session on the US markets. 
Via Chartmill
News headline image
MoonLake Immunotherapeutics Stock Draws Wall Street Attention Post Monday’s Plunge: Retail Sees Significant Upside ↗
Needham analyst Serge Belanger lowered the firm's price target on the stock to $20 from $66 but kept a ‘Buy’ rating on the shares. 
Via Stocktwits
News headline image
MLTX INVESTIGATION ALERT: MoonLake Immunotherapeutics Trial Results Triggers Securities Fraud Investigation after Stock Plummets 90% -- Investors Urged to Contact BFA Law
From Bleichmar Fonti & Auld LLP
Via Business Wire
News headline image
MLTX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Wall Street Lights Up as Cannabis Stocks Blaze Higher, Biotech Melts Down ↗
U.S. markets kicked off the week quietly, but certain stocks were anything but dull. Cannabis names surged after a Trump-endorsed CBD video went viral, while biotech firm MoonLake was crushed by... 
Via Chartmill
Topics Cannabis
News headline image
Wolfspeed, Tilray, Robinhood, Etsy, And Moonlake Immunotherapeutics: Why These 5 Stocks Are On Investors' Radars Today ↗
U.S. stocks advanced today, with the Nasdaq climbing about 107 points, or 0.48%, to 22,591.15. The S&P 500 added 0.26% to close at 6,661.21, while the Dow Jones Industrial Average edged up 0.15% to... 
Via Benzinga
Topics Stocks
News headline image
Crude Oil Falls Sharply; Carnival Posts Upbeat Earnings ↗
U.S. stocks traded mixed midway through trading, with the Dow Jones falling more than 50 points on Monday. The Dow traded down 0.12% to 46,190.92 while the NASDAQ rose 0.40% to 22,574.89. The S&P 500... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands at $5.5 million. Zura Bio (NASDAQ: ZURA) stock moved upwards by 42.94% to $3.44.... 
Via Benzinga
News headline image
MLTX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
Nasdaq Jumps 150 Points; US Pending Home Sales Rise ↗
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 150 points on Monday. Following the market opening Monday, the Dow traded up 0.19% to 46,333.68 while the NASDAQ rose... 
Via Benzinga
Topics Stocks
News headline image
MoonLake Crashes 89% On Mixed Results For Skin Disease Treatment ↗
MoonLake Immunotherapeutics stock crashed Monday after the company posted mixed results for its skin disease drug. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The market value of their outstanding shares is at $10.5 million. 
Via Benzinga
News headline image
Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday. Shares of Inventiva ADR (NASDAQ: IVA) fell sharply in today's pre-market trading following H1... 
Via Benzinga
Topics Stocks
News headline image
This Electronic Arts Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings... 
Via Benzinga
News headline image
Why Is MoonLake Immunotherapeutics Stock Crashing Premarket? ↗
RBC Capital downgraded the stock, calling the results a “near-miss” statistically and warning that the drug’s effect size looked uncompetitive. 
Via Stocktwits
News headline image
Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket ↗
Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its... 
Via Benzinga
News headline image
2 Small-Cap Biotech Stocks Well Positioned for a Breakout ↗
Clinical trial results expected in the weeks ahead could push shares of these small-cap drugmakers through the roof. 
Via The Motley Fool
News headline image
Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery ↗
Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE-689 trial. 
Via Benzinga
News headline image
Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta ↗
Byron Allen dials out, Salesforce logs in. Here are the various deal announcements of the past week plus bankruptcy updates. 
Via Benzinga
Topics Bankruptcy
News headline image
Signet Posts Upbeat Earnings, Joins Ferguson Enterprises, Dollar General And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Tuesday's session: gap up and gap down stocks ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday. 
Via Chartmill
News headline image
MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover ↗
The deal is being discussed ahead of key data from MoonLake in patients with a skin disease. 
Via Investor's Business Daily
News headline image
Tuesday's pre-market session: top gainers and losers ↗
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.